775 Phase Ib/II Study of XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) combination in metastatic melanoma refractory to prior immune checkpoint Inhibitor therapy with and without CNS disease

• Saya Jacob,
• Adil Daud,
• Zoe Quandt,
• Markee Micu,
• Katy K Tsai,
• Shahriar Yaghoubi

Affiliations

Saya Jacob

1UCSF, San Francisco, CA, USA

Adil Daud

2University of California, San Francisco, San Francisco, CA, USA

Zoe Quandt

University of California San Francisco, San Francisco, CA, USA

Markee Micu

1UCSF, San Francisco, CA, USA

Katy K Tsai

2University of California, San Francisco, San Francisco, CA, USA

Shahriar Yaghoubi

3Xencor, Inc., Beverly Hills, CA, USA